Company
Novo
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
10
9 still marketed
Novel approvals
5
Approvals since 2021
16
Originals and new uses
Phase 3 trials
368
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Wegovy new use Mar 19, 2026
- Wegovy approved Dec 22, 2025
- Wegovy new use Nov 21, 2025
- Ozempic new use Oct 17, 2025
- Wegovy new use Breakthrough therapyPriority reviewAug 15, 2025
- Rivfloza new use OrphanMar 27, 2025
- Ozempic new use Jan 28, 2025
- Ozempic new use Dec 9, 2024
- Wegovy new use Nov 27, 2024
- Wegovy new use Priority reviewMar 8, 2024
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07567001 · 5,610 participants (planned) · Start May 11, 2026 · Primary completion Jul 23, 2029
Drug: NNC0487-0111; Placebo · For: Obesity; Heart Failure
Sites: Alexander City, Alabama; Birmingham, Alabama; Fairhope, Alabama · 838 sites in all
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07564414 · 2,500 participants (planned) · Start May 21, 2026 · Primary completion Feb 23, 2028
Drug: Cagrisema; Semaglutide · For: Obesity; Type 2 Diabetes
Sites: Birmingham, Alabama; Pelham, Alabama; Gilbert, Arizona · 303 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07797335 · 1,778 participants (planned) · Start Aug 24, 2026 · Primary completion Jul 31, 2028
Drug: Zenagamtide; Insulin glargine U-100 · For: Type 2 Diabetes; Cardiovascular Risk
Sites: Birmingham, Alabama; Fairhope, Alabama; Montgomery, Alabama · 330 sites in all
- CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07207811 · 1,280 participants (planned) · Start Oct 2, 2025 · Primary completion Jun 29, 2029
Drug: NNC6019-0001; Placebo (NNC6019-0001) · For: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 299 sites in all
- AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07339423 · 1,150 participants (planned) · Start Feb 24, 2026 · Primary completion Jun 26, 2029
Drug: NNC0487-0111; Placebo (matched to NNC0487-0111) · For: Obesity
Sites: Miramar, Florida; Orlando, Florida; Conyers, Georgia · 72 sites in all
- AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07720271 · 950 participants (planned) · Start Aug 31, 2026 · Primary completion Jun 27, 2028
Drug: zenagamtide; Placebo · For: Overweight; Obesity
Sites: Anniston, Alabama; Birmingham, Alabama; Montgomery, Alabama · 41 sites in all
- A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutidePivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07668414 · 650 participants (planned) · Start Sep 22, 2026 · Primary completion Oct 10, 2028
Drug: Zenagamtide; Semaglutide and 2 more · For: Overweight; Obesity
Sites: Lancaster, California; Palm Springs, California; Pomona, California · 45 sites in all
- A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell DiseasePivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06612268 · 510 participants (planned) · Start Feb 17, 2025 · Primary completion Aug 27, 2027
Drug: Etavopivat; Placebo · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 175 sites in all
- A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or ThalassaemiaPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06609226 · 480 participants (planned) · Start Jan 10, 2025 · Primary completion Dec 30, 2030
Drug: Etavopivat A; Etavopivat B and 1 more · For: Sickle Cell Disease; Thalassemia
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 107 sites in all
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07253285 · 460 participants (planned) · Start Jan 8, 2026 · Primary completion Mar 20, 2030
Drug: Cagrilintide; Semaglutide and 2 more · For: Overweight; Obesity
Sites: Escondido, California; Hollywood, Florida; Jacksonville, Florida · 121 sites in all
Marketed drugs (9)
Newest FDA action first.
- Ozempic Semaglutide · 2017
- Wegovy Semaglutide · 2021
- Wegovy Semaglutide · 2025
- Saxenda Liraglutide · 2014
- Ozempic Semaglutide · 2019
- Xultophy 100/3.6 Insulin Degludec, Liraglutide · 2016
- Rivfloza Nedosiran Sodium · 2023
- Fiasp Penfill Insulin Aspart · 2017
- Tresiba Insulin Degludec · 2015
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.